4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 95 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $7,592,020 | -37.5% | 361,697 | -5.1% | 0.03% | -36.4% |
Q1 2024 | $12,141,177 | +2942.9% | 381,079 | +1835.0% | 0.04% | +2100.0% |
Q4 2023 | $399,000 | -56.9% | 19,694 | -72.9% | 0.00% | -60.0% |
Q3 2023 | $926,324 | -62.2% | 72,767 | -46.4% | 0.01% | -58.3% |
Q2 2023 | $2,451,394 | +27.2% | 135,661 | +21.0% | 0.01% | +20.0% |
Q1 2023 | $1,926,965 | – | 112,098 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |